Article
Medicine, General & Internal
Michael A. Puskarich, Nicholas E. Ingraham, Lisa H. Merck, Brian E. Driver, David A. Wacker, Lauren Page Black, Alan E. Jones, Courtney Fletcher, Andrew M. South, Thomas A. Murray, Christopher Lewandowski, Joseph Farhat, Justin L. Benoit, Michelle H. Biros, Kartik Cherabuddi, Jeffrey G. Chipman, Timothy W. Schacker, Faheem W. Guirgis, Helen T. Voelker, Joseph S. Koopmeiners, Christopher J. Tignanelli
Summary: This study found that oral administration of losartan did not improve the PaO2:FiO(2) ratio at 7 days in hospitalized patients with COVID-19 and acute lung injury. The use of losartan also did not improve secondary clinical outcomes and resulted in fewer vasopressor-free days compared to placebo.
Article
Medicine, Research & Experimental
Mauro G. Silva, Gerardo R. Corradi, Juan Perez Duhalde, Myriam Nunez, Eliana M. Cela, Daniel H. Gonzales Maglio, Ana Brizzio, Martin R. Salazar, Walter G. Espeche, Mariela M. Gironacci
Summary: This study found that COVID-19 patients have higher levels of ACE2 expression and enzymatic activity in their blood compared to healthy individuals, while levels of AngII and Ang-(1-7) are lower. Even when excluding COVID-19 patients under RAS blockade treatment, ACE2 expression and enzymatic activity remain higher in COVID-19 patients, suggesting the involvement of RAS in COVID-19.
BIOMEDICINE & PHARMACOTHERAPY
(2022)
Review
Neurosciences
Naif H. Ali, Hayder M. Al-Kuraishy, Ali I. Al-Gareeb, Ali K. Albuhadily, Rabab S. Hamad, Athanasios Alexiou, Marios Papadakis, Hebatallah M. Saad, Gaber El-Saber Batiha
Summary: This article discusses the pathophysiology of depression and the role of the brain renin-angiotensin system (RAS) in it. It is found that angiotensin-converting enzyme inhibitors and angiotensin receptor blockers may be effective in the treatment of depression. By regulating serotonin, brain-derived neurotrophic factor, mitochondrial dysfunction, oxidative stress, and neuroinflammation, these drugs can ameliorate the pathophysiology of depression.
CNS NEUROSCIENCE & THERAPEUTICS
(2023)
Article
Critical Care Medicine
Genevieve L. Y. Rocheleau, Terry Lee, Yassene Mohammed, David Goodlett, Kevin Burns, Matthew P. Cheng, Karen Tran, David Sweet, John Marshall, Arthur S. Slutsky, Srinivas Murthy, Joel Singer, David M. Patrick, Bin Du, Zhiyong Peng, Todd C. Lee, John H. Boyd, Keith R. Walley, Francois Lamontagne, Robert Fowler, Brent W. Winston, Greg Haljan, Donald C. Vinh, Alison McGeer, David Maslove, Santiago Perez Patrigeon, Puneet Mann, Kathryn Donohoe, Geraldine Hernandez, James A. Russell
Summary: This study examined the effects of angiotensin receptor blockers (ARBs) and angiotensin-converting enzyme (ACE) inhibitors in hospitalized COVID-19 patients, focusing on gender differences. The results showed that ARBs were associated with reduced use of ventilation and vasopressors in male patients, but not in female patients. Additionally, sex-based differences in the renin-angiotensin system (RAS) components may contribute to variations in outcomes and responses to ARBs in COVID-19.
CRITICAL CARE MEDICINE
(2022)
Article
Multidisciplinary Sciences
Mohitosh Biswas, Most. Sumaiya Khatun Kali
Summary: The use of ACE inhibitors and ARBs in COVID-19 patients was not associated with increased risk of mortality, severe clinical manifestations, or positive SARS-CoV-2 tests compared to patients not taking these medications. The findings suggest that discontinuation of ACE inhibitors or ARBs in treating COVID-19 patients may not be necessary based on current evidence.
SCIENTIFIC REPORTS
(2021)
Review
Cell Biology
Zheng Ma, Mei-Ping Wang, Lian Liu, Shuang Yu, Tian-Ran Wu, Lei Zhao, Ye-Ping Zhang, Hai-Feng Liang, Xin-Chun Yang
Summary: The meta-analysis suggests that the use of ACEI/ARB may increase the risk of COVID-19 infection in the general population, but not in hypertensive individuals. Additionally, ACEI/ARB usage was not associated with adverse outcomes in COVID-19 patients.
Article
Pharmacology & Pharmacy
Shao-Yu Yang, Tao-Min Huang, Tai-Shuan Lai, Nai-Kuan Chou, Chun-Hao Tsao, Yi-Ping Huang, Shuei-Liong Lin, Yung-Ming Chen, Vin-Cent Wu
Summary: The study found that preoperative use of ARBs was associated with a reduced risk of postoperative AKI, especially in high doses, while preoperative use of ACEIs or ARBs was both linked to reduced mortality and did not increase the risk of hyperkalemia.
FRONTIERS IN PHARMACOLOGY
(2021)
Article
Dentistry, Oral Surgery & Medicine
Gulbahar Ustaoglu, Emrah Erdal, Zeynep Karas
Summary: This study aimed to evaluate the occurrence rate of drug-induced gingival overgrowth in patients treated with ACE inhibitors, ARBs, and CCBs, with highest rate found in the amlodipine group. There was a significant relationship between drug dosage and DIGO, while no association was found with the duration of therapy.
Article
Cardiac & Cardiovascular Systems
Rohan Khera, Callahan Clark, Yuan Lu, Yinglong Guo, Sheng Ren, Brandon Truax, Erica S. Spatz, Karthik Murugiah, Zhenqiu Lin, Saad B. Omer, Deneen Vojta, Harlan M. Krumholz
Summary: The study found that ACE inhibitors and ARBs were not significantly associated with the risk of COVID-19 hospitalization or mortality. Despite some tendency to lower hospitalization risk in older individuals, recent data consistency supports this conclusion.
JOURNAL OF THE AMERICAN HEART ASSOCIATION
(2021)
Article
Cardiac & Cardiovascular Systems
Jaejin An, Rong Wei, Hui Zhou, Tiffany Q. Luong, Michael K. Gould, Matthew T. Mefford, Teresa N. Harrison, Beth Creekmur, Ming-Sum Lee, John J. Sim, Jeffrey W. Brettler, John P. Martin, Angeline L. Ong-Su, Kristi Reynolds
Summary: The study found that the use of ACEIs or ARBs was not significantly associated with COVID-19 infection among patients with hypertension. However, there was a lower odds of COVID-19 infection among adults over 85 years old using ACEIs, suggesting that further investigation is warranted.
JOURNAL OF THE AMERICAN HEART ASSOCIATION
(2021)
Article
Peripheral Vascular Disease
Zhenhong Deng, Jingru Jiang, Jia Wang, Dong Pan, Yingying Zhu, Honghong Li, Xiaoni Zhang, Xiaohuan Liu, Yongteng Xu, Yi Li, Yamei Tang
Summary: In patients with hypertension and mild cognitive impairment, angiotensin receptor blockers are associated with a lower risk of progression to dementia compared with ACE inhibitors and other classes of antihypertensive medications. Further investigations in larger prospective cohorts or clinical trials are needed to confirm these findings.
Review
Peripheral Vascular Disease
Zhen-Yu Zhang, Yu-Ling Yu, Kei Asayama, Tine W. Hansen, Gladys E. Maestre, Jan A. Staessen
Summary: Additional digital content is available in the text.
Article
Peripheral Vascular Disease
Laura Semenzato, Jeremie Botton, Jerome Drouin, Berangere Baricault, Clementine Vabre, Francois Cuenot, Laetitia Penso, Philippe Herlemont, Emilie Sbidian, Alain Weill, Rosemary Dray-Spira, Mahmoud Zureik
Summary: Recent evidence suggests that hypertensive patients treated with ACE inhibitors or ARBs may have a lower risk of COVID-19 hospitalization and intubation/death compared to those treated with CCBs. This contradicts initial hypotheses regarding the association between renin-angiotensin-aldosterone system inhibitors and COVID-19 risk, raising new questions for further research.
Article
Peripheral Vascular Disease
Gary Tse, Jiandong Zhou, Sharen Lee, Wing Tak Wong, Xintao Li, Tong Liu, Zhidong Cao, Daniel Dajun Zeng, Abraham K. C. Wai, Ian Chi Kei Wong, Bernard Man Yung Cheung, Qingpeng Zhang
Summary: The study found a significant relationship between ACEI/ARB use and COVID-19 positivity and severe disease after adjusting for significant confounders. There were no significant differences in COVID-19 positivity or disease severity between ACEI and ARB use.
JOURNAL OF HYPERTENSION
(2021)
Review
Transplantation
Panagiotis Georgianos, Georgios Tziatzios, Stefanos Roumeliotis, Vasilios Vaios, Vasiliki Sgourogoulou, Dimitrios G. Tsalikakis, Vassilios Liakopoulos, Rajiv Agarwal
Summary: This meta-analysis study found that the use of ACEIs/ARBs is not associated with a significantly lower risk of cardiovascular events and all-cause mortality among patients on dialysis when compared with placebo or no add-on treatment.
NEPHROLOGY DIALYSIS TRANSPLANTATION
(2023)
